血小板生成素水平可预测免疫性血小板减少症患者对艾曲泊帕与罗米司亭治疗的反应
该回顾性分析纳入67例已知基线血小板生成素(TPO)水平的免疫性血小板减少症(ITP)患者,其中37例接受艾曲泊帕、46例接受罗米司亭治疗。多因素logistic回归显示TPO水平与各类治疗反应概率显著相关,ROC分析确定艾曲泊帕与罗米司亭的最佳TPO阈值分别为≤136 pg/mL和≤209 pg/mL。结论认为较低TPO水平预示更高的反应概率与幅度。
要点
- TPO每升高10 pg/mL,艾曲泊帕总体反应OR为0.524(95%CI 0.327,0.837),罗米司亭为0.905(95%CI 0.844,0.970)。
- TPO水平与总体反应呈负相关:艾曲泊帕r=-0.719(P<.001),罗米司亭r=-0.584(P<.001)。
- ROC分析确定预测反应的最佳TPO阈值:艾曲泊帕≤136 pg/mL,罗米司亭≤209 pg/mL。
核心结论
- TPO水平可预测ITP患者对艾曲泊帕和罗米司亭的治疗反应,较低水平预示更高的反应概率和幅度。
研究设计与样本
- 回顾性分析纳入67例已知基线TPO水平并接受TPO受体激动剂治疗的ITP患者,其中37例接受艾曲泊帕、46例接受罗米司亭。
主要发现
- 多因素logistic回归显示TPO水平与所有类别治疗反应概率显著相关。
- TPO每升高10 pg/mL,艾曲泊帕总体反应OR为0.524(95%CI 0.327,0.837),罗米司亭为0.905(95%CI 0.844,0.970)。
- TPO水平与所有类别反应呈负相关;总体反应艾曲泊帕r=-0.719(P<.001),罗米司亭r=-0.584(P<.001)。
- ROC分析确定最佳TPO阈值:艾曲泊帕≤136 pg/mL,罗米司亭≤209 pg/mL。
- 多数无反应者TPO水平高,但加用低剂量泼尼松后出现反应。
关键数值与推荐
- 艾曲泊帕总体反应OR 0.524(95%CI 0.327,0.837),罗米司亭OR 0.905(95%CI 0.844,0.970),均为TPO每升高10 pg/mL。
- 总体反应相关系数:艾曲泊帕r=-0.719(P<.001),罗米司亭r=-0.584(P<.001)。
- 预测反应TPO阈值:艾曲泊帕≤136 pg/mL,罗米司亭≤209 pg/mL。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Thrombopoietin receptor agonists (TPO-RAs) are used to treat immune thrombocytopenia (ITP), but predicting clinical response to TPO-RAs before initiation is not possible. To determine whether endogenous TPO levels predict treatment response to TPO-RAs we performed a retrospective analysis of ITP patients with known baseline TPO levels who received TPO-RAs. Data was collected for ITP patients with a baseline TPO level treated with eltrombopag or romiplostim. Multiple logistic regression was used to model the probability of 3 classes of treatment response (overall, moderate, and superior) based on TPO level; receiver operating characteristic (ROC) analysis was performed to identify optimal TPO thresholds for response; correlations between TPO level and various response characteristics were analyzed. A total of 67 patients (37 receiving eltrombopag and 46 receiving romiplostim) were included. Logistic regression models demonstrated a significant predictive relation between TPO level and probability of all classes of response; per 10 pg/mL TPO increase, odds ratio for overall response to eltrombopag was 0.524 (95% CI 0.327, 0.837) and romiplostim was 0.905 (95% CI, 0.844, 0.970). TPO level was inversely correlated with all classes of response; for overall response, r = -0.719 (P < .001) for eltrombopag and r = -0.584 (P < .001) for romiplostim. ROC analysis identified TPO thresholds of ≤136 pg/mL (eltrombopag) and ≤209 pg/mL (romiplostim) as optimally discriminating between responders and nonresponders. Most non-responders had high TPO levels but did respond after addition of low-dose prednisone. In conclusion, TPO levels predict response to eltrombopag and romiplostim in ITP patients, with lower levels predicting improved probability and magnitude of response.
引用
- Al-Samkari H, Kuter DJ. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia. Am J Hematol. 2018. PMID: 30187942. doi:10.1002/ajh.25275
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。